Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 1;29(5):438-445.
doi: 10.1097/MCC.0000000000001074. Epub 2023 Jul 31.

Severe infections caused by difficult-to-treat Gram-negative bacteria

Silvia Dettori  1 , Federica Portunato  1 , Antonio Vena  1   2 , Daniele Roberto Giacobbe  1   2 , Matteo Bassetti  1   2
Affiliations
Review

Severe infections caused by difficult-to-treat Gram-negative bacteria

Silvia Dettori et al. Curr Opin Crit Care. .

Abstract

Purpose of review: Antimicrobial resistance (AMR) in Gram-negative bacteria (GNB) poses a significant global health concern, contributing to increased infections, mortality rates, and healthcare costs. This review discusses the main clinical manifestations, therapeutic options, and recent findings in managing antibiotic-resistant GNB, with a focus on difficult-to-treat infections.

Recent findings: Difficult-to-treat resistance (DTR) is a novel classification that identifies GNB exhibiting intermediate or resistant phenotypes to first-line agents in the carbapenem, beta-lactam, and fluoroquinolone categories. The main pathogens implicated in severe infections include DTR Enterobacterales, DTR Pseudomonas aeruginosa , and DTR Acinetobacter baumannii. Although the clinical implications of DTR strains are still under investigation, certain studies have linked them to prolonged hospital stays and poor patient outcomes.

Summary: Severe infections caused by DTR-GNB pose a formidable challenge for healthcare providers and represent a growing global health issue. The proper administration and optimization of novel antibiotics at our disposal are of paramount importance for combating bacterial resistance and improving patient prognosis.

PubMed Disclaimer

Conflict of interest statement

M.B. has participated in the past 5 years in advisory boards, research grants and/or received speaker bureau from Astellas, Pfizer, MSD, Gilead, Angelini, Bayer, Biomerieux, Cidara, Menarini, and Shionogi. The other authors declare no conflicts of interest.

Figures

Box 1
Box 1
no caption available
See this image and copyright information in PMC

References

    1. US Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2019. Available at: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-re.... [Accessed 20 February 2023]
    1. Babiker A, Clarke LG, Saul M, et al. . Changing epidemiology and decreased mortality associated with carbapenem-resistant Gram-negative bacteria, 2000–2017. Clin Infect Dis 2021; 73:e4521–e4530. - PMC - PubMed
    1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022; 399:629–655. - PMC - PubMed
    1. 2019 AR Threats Report. Available at: https://www.cdc.gov/drugresistance/biggest-threats.html. [Accessed 20 February 2023]
    1. Magiorakos A-P, Srinivasan A, Carey RB, et al. . Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18:268–281. - PubMed